Xeris Biopharma (NASDAQ:XERS) Earns “Outperform” Rating from Oppenheimer

Posted by George Bondi on Nov 6th, 2026

Xeris Biopharma (NASDAQ:XERS – Get Free Report)‘s stock had its “outperform” rating reaffirmed by research analysts at Oppenheimer in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $21.00 target price on the stock, up from their previous target price of $18.00. Oppenheimer‘s target price would indicate a potential upside of 45.95% from the stock’s previous close.

A number of other analysts also recently issued reports on the stock. Barclays lifted their price objective on shares of Xeris Biopharma from $12.00 to $14.00 and gave the company an “overweight” rating in a report on Tuesday, October 6th. Wall Street Zen upgraded Xeris Biopharma from a “hold” rating to a “buy” rating in a report on Saturday, September 19th. Weiss Ratings downgraded Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Piper Sandler reissued a “neutral” rating and issued a $12.00 price objective (up from $8.00) on shares of Xeris Biopharma in a research report on Friday. Finally, HC Wainwright boosted their target price on Xeris Biopharma from $10.00 to $18.00 and gave the stock a “buy” rating in a report on Friday. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.20.

Read Our Latest Research Report on Xeris Biopharma

Xeris Biopharma Stock Up 10.0%

Shares of XERS traded up $1.31 during midday trading on Friday, hitting $14.39. The stock had a trading volume of 3,518,505 shares, compared to its average volume of 2,083,847. The firm has a market cap of $2.62 billion, a price-to-earnings ratio of -131.25 and a beta of 0.61. The company has a 50 day simple moving average of $9.49 and a two-hundred day simple moving average of $7.58. Xeris Biopharma has a twelve month low of $5.25 and a twelve month high of $14.64. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02.

Xeris Biopharma (NASDAQ:XERS – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. The business had revenue of $107.23 million during the quarter, compared to the consensus estimate of $101.68 million. On average, analysts anticipate that Xeris Biopharma will post 0.07 EPS for the current year.

Insider Buying and Selling at Xeris Biopharma

In other news, insider Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $10.23, for a total value of $153,450.00. Following the completion of the sale, the insider directly owned 1,584,208 shares in the company, valued at approximately $16,206,447.84. The trade was a 0.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $10.23, for a total value of $255,750.00. Following the completion of the sale, the insider owned 1,086,130 shares of the company’s stock, valued at approximately $11,111,109.90. This trade represents a 2.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 148,332 shares of company stock valued at $1,409,221 in the last quarter. Company insiders own 4.35% of the company’s stock.

Hedge Funds Weigh In On Xeris Biopharma

Hedge funds have recently added to or reduced their stakes in the stock. Chicago Partners Investment Group LLC lifted its position in shares of Xeris Biopharma by 16.3% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 13,286 shares of the company’s stock valued at $136,000 after acquiring an additional 1,861 shares during the period. AlphaCentric Advisors LLC grew its holdings in shares of Xeris Biopharma by 4.2% during the 3rd quarter. AlphaCentric Advisors LLC now owns 48,489 shares of the company’s stock worth $464,000 after purchasing an additional 1,940 shares in the last quarter. Allworth Financial LP grew its holdings in shares of Xeris Biopharma by 86.4% during the 2nd quarter. Allworth Financial LP now owns 4,315 shares of the company’s stock worth $34,000 after purchasing an additional 2,000 shares in the last quarter. Jacksonville Wealth Management LLC increased its position in shares of Xeris Biopharma by 11.8% in the third quarter. Jacksonville Wealth Management LLC now owns 19,000 shares of the company’s stock worth $182,000 after purchasing an additional 2,000 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Xeris Biopharma by 7.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 33,266 shares of the company’s stock worth $332,000 after purchasing an additional 2,190 shares during the period. Institutional investors own 42.75% of the company’s stock.

Xeris Biopharma News Roundup

Here are the key news stories impacting Xeris Biopharma this week:

Positive Sentiment: Q3 results topped estimates: Xeris reported earnings of $0.06 per share versus consensus of $0.03, and revenue of $107.23 million versus expectations of $101.68 million. The earnings growth and revenue beat helped fuel the stock’s advance. Xeris Biopharma Shares Jump After Q3 Results Top Estimates
Positive Sentiment: Stronger outlook for Recorlev: CEO John Shannon said the drug could reach $1 billion in annual sales three to four years earlier than previously expected, raising expectations for future growth. The company also updated its FY2030 earnings guidance. Xeris CEO sees Recorlev nearing $1B in annual sales
Positive Sentiment: HC Wainwright turned more bullish: The firm raised its price target to $18 from $10 and assigned XERS a “buy” rating, implying further upside at the time of its report.
Neutral Sentiment: Analyst views are mixed: Piper Sandler kept its “neutral” rating while raising its target to $12 from $8. That target is below the recent share price, tempering the more optimistic outlook from HC Wainwright.
Negative Sentiment: Insider sales: Several insiders sold shares under pre-arranged Rule 10b5-1 plans. The sales were small relative to their remaining holdings and were scheduled in advance, so they may be a limited concern rather than a clear signal about the business.

Xeris Biopharma Company Profile

(Get Free Report)

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.